| Yazarlar (9) |
Doç. Dr. Selin ÖZKAN KOTİLOĞLU
Kırşehir Ahi Evran Üniversitesi, Türkiye |
D. Kaya-Akyuzlu
|
|
M. A. Yildirim
|
|
M. Danisman
|
|
C. Bozmaoglu
|
|
K. C. Tok
|
|
M. Gumustas
|
|
I. Ozgur-Ilhan
|
|
S. Suzen
|
| Özet |
| Alcohol withdrawal syndrome (AWS) is a condition diagnosed in more than 50% of alcohol use disorder (AUD) patients, ranging from mild to severe which requiring different pharmacological treatments. Benzodiazepines are considered as gold standard for AWS. Diazepam, a benzodiazepine is more effective than other benzodiazepines in preventing delirium and alleviating withdrawal symptoms, primarily due to its long half-life. Diazepam is converted into its primary metabolite, desmethyldiazepam, through the action of enzymes encoded by the CYP2C19 and CYP3A4 genes. Studies have shown that variations in the CYP2C19 gene can lead to differences in enzyme activity, which may vary between individuals. This study aims to explore the effect of CYP2C19*2 gene polymorphism, which known as poor metaboliser, on the plasma concentrations of diazepam (DZP) and desmethyldiazepam (DMDZP) in Turkish … |
| Anahtar Kelimeler |
| Bildiri Türü | Tebliğ/Bildiri |
| Bildiri Alt Türü | Özet Metin Olarak Yayınlanan Tebliğ (Uluslararası Kongre/Sempozyum) |
| Bildiri Niteliği | Web of Science Kapsamındaki Kongre/Sempozyum |
| Doi Numarası | 10.1016/j.toxlet.2025.07.243 |
| Bildiri Dili | İngilizce |
| Kongre Adı | |
| Kongre Tarihi | / |
| Basıldığı Ülke | |
| Basıldığı Şehir |
| Atıf Sayıları |
